Alivus Life Sciences Latest Share Price (ALIVUS)
TODAY IN ONE LINE
ALIVUS fell 1.4% on average volume, lagging Nifty's 0.1% move.
With a market cap of ₹16,528.71 Cr., it trades at a P/E of 27.35. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Alivus Life Sciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 14.5% YoY
- ●Healthy Operating MarginsOPM is structurally strong at 31.4%
- ●High Promoter HoldingPromoters hold 74.9% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 18.2% outpacing sales growth of 4.5%
Latest Alivus Life Sciences News
What changed recently?
Recent events, corporate actions, and announcements.
Alivus Life Sciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Alivus Life Sciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Alivus Life Sciences Limited trades at a P/E of 27.35× and P/B of 4.95×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Alivus Life Sciences Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Alivus Life Sciences Limited — derived from the latest tape, not yesterday's close.
Alivus Life Sciences Limited last traded at ₹1,350.9 with an intraday range of ₹1,331.1–₹1,384.7 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1350.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1487.23 | +136.33 | +10.09% |
| R3 | 1433.63 | +82.73 | +6.12% |
| R2 | 1409.17 | +58.27 | +4.31% |
| R1 | 1380.03 | +29.13 | +2.16% |
| PIVOT | 1355.57 | 4.67 | 0.35% |
| CURRENT | 1350.90 | — | — |
| S1 | 1326.43 | -24.47 | -1.81% |
| S2 | 1301.97 | -48.93 | -3.62% |
| S3 | 1272.83 | -78.07 | -5.78% |
| S4 | 1219.23 | -131.67 | -9.75% |
ALIVUS is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹1362.2–₹1384.7
Trading Below opening range, showing Bearishness
Alivus Life Sciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Alivus Life Sciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Alivus Life Sciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹16,528.71 Cr. and reported EPS of ₹49.05.
Alivus Life Sciences segment analysis : revenue and profit mix.
Disclosed business segments at Alivus Life Sciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Alivus Life Sciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Alivus Life Sciences Limited.
Our AI distills the core fundamental drivers supporting Alivus Life Sciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Alivus Life Sciences Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Debt-free balance sheet with D/E ratio 0.00x signals exceptional financial stability and flexibility.
Operating margin 28.29% TTM substantially exceeds peer median 16–25% range significantly.
Net profit margin 22.05% TTM reflects superior cost control and operational efficiency versus peers.
ROE 18.36% surpasses sector average, demonstrating efficient capital deployment and returns.
Promoter holding 74.87% signals strong founder commitment and long-term governance stability.
Key Risks.
Latest quarterly EPS grew 14.7% YoY, but zero quarterly sales variation signals near-term stagnation.
P/E ratio 23.54x TTM elevated relative to forward P/E 18.78x suggests earnings deceleration ahead.
Dividend yield 0.36% minimal, limiting income appeal for yield-focused investors significantly.
5-year revenue growth 0% indicates limited long-term expansion despite TTM 6.1% growth.
Average trading volume 97,728 shares daily creates liquidity risks and price stability concerns.
Flip Conditions.
Valuation risk. a P/E above 36 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Income thesis breaks if the dividend is cut or yield falls below 0.18%.
Alivus Life Sciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Alivus Life Sciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Alivus Life Sciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Alivus Life Sciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Alivus Life Sciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Alivus Life Sciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Alivus Life Sciences Limited stood at 45.1% of traded volume, against a 20-day average of 49.7%.
Alivus Life Sciences announcements: results, concalls, ratings, M&A.
Filings Alivus Life Sciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Alivus Life Sciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 114 documents below.
Press Release
Alivus Life Sciences Limited has informed the Exchange regarding a press release dated August 18, 2026, titled "Alivus Life Sciences announces…
Outcome of Board Meeting
Enclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.
Analysts/Institutional Investor Meet/Con. Call Updates
Alivus Life Sciences Limited has informed the Exchange about Schedule of meet of Investor/Analyst.
Copy of Newspaper Publication
Alivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 15th Annual General Meeting and e-voting…
Updates
Alivus Life Sciences Limited has informed the Exchange regarding 'Business Responsibility & Sustainability Report for FY 2025-26'.
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Alivus Life Sciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Alivus Life Sciences has declared, sequenced by announce and record date.
Alivus Life Sciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Alivus Life Sciences Limited: business, sector, key facts.
What Alivus Life Sciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Alivus Life Sciences Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ALIVUS, BSE: 543322.
Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, is an Indian pharmaceutical company specializing in the development, manufacturing, and marketing of non-commoditized Active Pharmaceutical Ingredients (APIs). These APIs are crucial components used in the production of various finished dosage forms of medications.
The company's portfolio encompasses a wide range of APIs targeting diverse therapeutic areas. This includes cardiovascular disease treatments (like olmesartan, telmisartan, and perindopril), central nervous system disorder medications (zonisamide), diabetes treatments (sitagliptin), gastrointestinal drugs (solifenacin, mirabegron), oncology therapies, pain management drugs, and anti-infectives (atovaquone). Additionally, they offer adapalene (used in dermatology) and rosuvastatin (a cholesterol-lowering drug).
A significant aspect of Alivus's business model is the provision of contract development and manufacturing services (CDMO). This means they produce APIs not only for their own branded formulations but also for other multinational corporations and specialty pharmaceutical companies. This CDMO segment allows them to leverage their manufacturing expertise and capacity for a broader client base, contributing to revenue diversification.
Alivus boasts a global reach, exporting its APIs to major markets including Europe, North America, Latin America, Japan, and other international destinations. This broad geographical reach underscores the company’s success in establishing itself as a significant player in the global API market.
The company, a subsidiary of Nirma Limited, was incorporated in 2011 and is headquartered in Mumbai, India. Its recent name change to Alivus Life Sciences Limited, effective December 2024, reflects a potential strategic repositioning or branding effort within the pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about Alivus Life Sciences Limited (ALIVUS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Alivus Life Sciences Limited (ALIVUS)?
The current share price of Alivus Life Sciences Limited (ALIVUS) is ₹1,350.90. Today, the stock has declined by ₹19.10 (1.39%), trading in a range of ₹1,331.10 to ₹1,384.70. The stock opened at ₹1,365.60 with a trading volume of 69,399 shares.
02Is Alivus Life Sciences Limited stock a good investment for long-term?
Alivus Life Sciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹16,528.71 Cr., P/E ratio of 27.35, ROE of 0%, and ROCE of 0%. The dividend yield stands at 0.37%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Alivus Life Sciences Limited stock?
The 52-week high price of Alivus Life Sciences Limited (ALIVUS) is ₹1,418.00, while the 52-week low is ₹819.00. Currently trading at ₹1,350.90, the stock is 64.95% above its 52-week low and 4.73% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Alivus Life Sciences Limited stock at the current price?
Whether to buy Alivus Life Sciences Limited stock at ₹1,350.90 depends on multiple factors. The stock is currently trading with a P/E ratio of 27.35 and P/B ratio of 4.95. Today's performance shows a loss of 1.39%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Alivus Life Sciences Limited and when is the next dividend?
Alivus Life Sciences Limited offers a dividend yield of 0.37%, which means for every ₹100 invested at the current price of ₹1,350.90, you can expect to receive approximately ₹0.37 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06How is Alivus Life Sciences Limited stock performing today in the market?
Alivus Life Sciences Limited stock opened at ₹1,365.60 and is currently trading at ₹1,350.90, showing a decline of ₹19.10 (1.39%). The intraday high is ₹1,384.70 and low is ₹1,331.10. The trading volume stands at 69,399 shares, indicating moderate market participation today.
07What is the P/E ratio of Alivus Life Sciences Limited and what does it indicate?
Alivus Life Sciences Limited has a Price-to-Earnings (P/E) ratio of 27.35, which means investors are willing to pay 27.35 for every ₹1 of earnings. With an EPS of ₹49.05, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
08What is the market capitalization of Alivus Life Sciences Limited?
Alivus Life Sciences Limited has a market capitalization of ₹16,528.71 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,350.90) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
The data, ratios and commentary about Alivus Life Sciences Limited (ALIVUS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.